Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2013

View Archived Issues

Elimination of leukemia stem cells observed for PF-04449913

Novel oncolytic agents with epigenetic targets described

Shire updates accomplishments of fourth quarter 2012

Small molecules targeting RNA improve experimental myotonic dystrophy type 1

Trial of temsirolimus in prostate cancer stopped prematurely

Boehringer Ingelheim divulges new LTA-4 hydrolase inhibitors

Georgia State University patents novel cyanine dyes for cancer

Abbott Laboratories prepares new protein kinase inhibitors

German group discloses novel TRPV1 ligands

Researchers at Allergan disclose novel alpha2-adrenoceptor agonists

CS-6 shows activity against ovarian cancer stem cells

PIQUR Therapeutics secures funding to develop innovative anticancer therapies

Roche and Chiasma enter into a collaboration agreement for Octreolin

FDA grants orphan drug status to SOV's testosterone undecanoate

Idursulfase beta gains orphan drug status in U.S.

FDA grants orphan drug status to diabetes vaccine candidate

Regeneron and Bayer initiate new phase III aflibercept study

FDA accepts lixisenatide NDA for review

Theracrine synthesizes new fascin inhibitors for cancer

Vorsetuzumab mafodotin shows promising activity in patients with CD70-positive RCC

Edison reports initiation of phase II study of EPI-743

New androgen receptor agonists divulged by Novartis

Novel inhibitors of tankyrase synthesized at Novartis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...